Search All News
Columbia research seven years in the making highlights potential therapeutic target for neurodegenerative disease
Dr. Lawrence Honig, professor of neurology at Columbia University Irving Medical Center, speaks about the new Alzheimer drug trial results
"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
- June 28, 2021
The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 a year, to limit the financial impact
- June 8, 2021
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
- June 4, 2021
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.
Source:ForbesMay 21, 2021
It is well established that people who had fewer opportunities to receive education when they were children are at higher risk for Alzheimer’s disease later in life, noted Dr. Jennifer Manly
Source:CUIMC NewsroomMarch 30, 2021
A new study on COVID-19 patients with dementia led by James Noble, MD, MS associate professor of neurology at CUIMC
- March 24, 2021
Inaugural Neurology Clinician of the Year Award
- January 25, 2021
The American Academy of Neurology (AAN) has honored Dr. James Noble, associate professor of neurology in the Division of Aging and Dementia, with a 2021 A. B. Baker Teacher Recognition Award.
Source:AlzforumDecember 11, 2020
It is difficult to isolate large quantities of microglia from human brain. That’s why scientists still know little about the different ways these cells rear up in health and disease.